Related references
Note: Only part of the references are listed.Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease Efficacy, tolerability, and patient experience
Jyotsna Mullur et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2022)
Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease: a case series
Lorena Miss Ozuna et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2022)
Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis
Qingwu Wu et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2022)
Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease
Hannah Wangberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization
Tamara Quint et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials
Joaquim Mullol et al.
ALLERGY (2022)
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis
[Anonymous]
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial
Claus Bachert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease
S. Shahzad Mustafa et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2021)
Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series
Hannah Martin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology
Whitney W. Stevens et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
Tim W. Harrison et al.
LANCET RESPIRATORY MEDICINE (2021)
Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab
Mattis Bertlich et al.
MEDICINE (2021)
Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting
Nicole Bavaro et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease
S. Shahzad Mustafa et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)
Aspirin desensitization in NSAID-exacerbated respiratory disease and its outcomes in the clinical course of asthma: A systematic review of the literature and meta-analysis
Isabel Eraso et al.
PLOS ONE (2021)
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
Joseph K. Han et al.
LANCET RESPIRATORY MEDICINE (2021)
Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease A Randomized Controlled Trial
Hiroaki Hayashi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Clinical Control of CSU with Antihistamines Allows for Tolerance of NSAID-Exacerbated Cutaneous Disease
Jorge Sanchez et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)a EAACI position paper
Marek L. Kowalski et al.
ALLERGY (2019)
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD
Tanya M. Laidlaw et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Mepolizumab utility in successful aspirin desensitization in aspirin-exacerbated respiratory disease in a refractory case
Mahboobeh Mahdavinia et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)
Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease
Tiffany Jean et al.
ALLERGY AND ASTHMA PROCEEDINGS (2019)
Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease
Saangyoung E. Lee et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2019)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert et al.
LANCET (2019)
Mepolizumab for the treatment of aspirin-exacerbated respiratory disease associated with coronary spasm
David Hagin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
NSAID-induced reactions: classification, prevalence, impact, and management strategies
Natalia Blanca-Lopez et al.
JOURNAL OF ASTHMA AND ALLERGY (2019)
Omalizumab can inhibit respiratory reaction during aspirin desensitization
David M. Lang et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Samter's Triad: State of the Art
Sung-Dong Kim et al.
CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY (2018)
Aspirin tolerance in patients with nonsteroidal anti-inflammatory druge exacerbated respiratory disease following treatment with omalizumab
Elsa Phillips-Angles et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Cofactors and comorbidities in patients with aspirin/NSAID hypersensitivity
M. Sanchez-Borges et al.
ALLERGOLOGIA ET IMMUNOPATHOLOGIA (2017)
Aspirin challenge and desensitization: how, when and why
Gabriele Cortellini et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Chronic Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease
Neha M. Dunn et al.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2016)
Aspirin or Nonsteroidal Anti-inflammatory Drug-Exacerbated Chronic Rhinosinusitis
Dennis K. Ledford et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2016)
Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Inmaculada Dona et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity
D. R. Morales et al.
ALLERGY (2015)
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials
Daniel R. Morales et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA
M. L. Kowalski et al.
ALLERGY (2011)